|
A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER. |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences |
|
Research Funding - Abbvie; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Corvus Pharmaceuticals; Genentech/Roche; Lilly; Threshold Pharmaceuticals |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Novartis; Pfizer; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Takeda |
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda |
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche/Genentech |
|
|
|
Speakers' Bureau - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Pfizer |
Research Funding - Abbvie; AstraZeneca; ICON Clinical Research; Lilly; MSD; PAREXEL; PPD; Quintiles; Roche |
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil |
|
|
Honoraria - Bristol-Myers Squibb; Takeda |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; Pfizer; Roche |
Research Funding - Merck Serono (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche |
|
|
Consulting or Advisory Role - Lilly |
Research Funding - Lilly (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche |
Speakers' Bureau - Boehringer Ingelheim |
Research Funding - AstraZeneca |
|
|
Consulting or Advisory Role - AstraZeneca; Roche |
Speakers' Bureau - Boehringer Ingelheim; Lilly |
Research Funding - AstraZeneca |
|
|
Speakers' Bureau - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - MSD |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
Honoraria - Amgen; AstraZeneca; BMS Brazil; Boehringer Ingelheim; Lilly; MSD; Novartis; Pfizer; Roche |